Logo
x

Search category

Subscribe Now

Sumitomo Pharma Oncology

Sumitomo Pharma Oncology’s DSP-5336 Receives the US FDA’s Orphan Drug Designation for the Treatment of Acute Myeloid Leukemia

Sumitomo Pharma Oncology’s DSP-5336 Receives the US FDA’s Orphan Drug Designation for the Treatment of Acute Myeloid Leukemia

  • August 4, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.